Feeling Blue: bluebird bio cuts staff by 30%, prepares for FDA decision

Following the ongoing trend in the pharmaceutical industry, bluebird bio has orchestrated a restructuring that includes saving financially and cutting staff. The restructuring is designed to prolong the company’s budget as it awaits decisions from the U.S. Food and Drug Administration (FDA).